CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioPharma Dive
Original article

Latigo IPO raises nearly $350M for pain drug development

IPO/OfferingPositive
AI Analysis

Summary

Latigo completed an IPO raising nearly $350M to fund development of non-opioid, ion-channel-blocking pain drugs, positioning itself to compete with Vertex and Lilly in this emerging market segment.

Importance:7/10
Sentiment:
0.60
IPOpain managementnon-opioidion-channel-blockingcapital raise
Related Companies

Read the original article

Published by BioPharma Dive on August 7, 2026 12:00 PM

Read Original